Specialised Therapeutics Australia (STA) is dedicated to working with leading biotechnology and pharmaceutical companies worldwide to make specialised therapies available to people living in Australia and New Zealand.
STA is an independent and privately owned company based in Melbourne, Australia. Carlo Montagner and Bozena Zembrzuski, who are both highly experienced globally in pharmaceutical commercialisation, founded STA in 2007.
At STA, our primary objective is to enable people living in Australia and New Zealand with high unmet medical needs, unrestricted access to breakthrough acute care therapies.
The STA therapeutic portfolio and pipeline currently encompasses oncology and infectious diseases. STA also has interests in other therapies such as haematology, respiratory, dermatology, endocrinology and central nervous system disorders.
STA has launched in Australia and New Zealand two leading therapies in the field of oncology: ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer and ALOXI® (palonosetron HCl) for the amelioration of nausea and vomiting associated with many cancer therapies
Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries.
Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival.
Specialised Therapeutics Australia (STA) is pleased to announce the results of the phase III, randomised, international study (CA033) of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in chemotherapy-naïve patients with metastatic melanoma.
Patients with an aggressive form of brain tumour, glioblastoma multiforme (GBM), have been given access to a new brain tumour visualisation drug, Gliolan® (5-aminolevulinic acid), at The Royal Melbourne Hospital.
Novel drug which improves visualisation and resection of malignant brain tumours now widely available. Twice as many patients are without progression of brain cancer six months after surgery with GLIOLAN. To date over 100 Australian patients have been treated with GLIOLAN via the Federal Government’s Special Access Scheme.
ABRAXANE plus gemcitabine demonstrated highly statistically significant and clinically meaningful results across primary and key secondary endpoints and patient subgroups. ABRAXANE plus gemcitabine patients showed 59% higher chance of survival at one year; survival rates doubled at two years.
In a randomised, open-label, international study (CA033), ABRAXANE showed a statistically significant improvement in progression-free survival (PFS) in chemotherapy-naïve patients with metastatic melanoma compared to patients receiving dacarbazine chemotherapy.
Helsinn Healthcare SA and STA reinforce their Cancer Supportive Care Alliance in Australia and New Zealand with a Distribution and License Agreement for the innovative phase III ghrelin receptor agonist.